TW202342477A - 二醯基甘油激酶(DGK) α抑制劑及其用途 - Google Patents

二醯基甘油激酶(DGK) α抑制劑及其用途 Download PDF

Info

Publication number
TW202342477A
TW202342477A TW112107272A TW112107272A TW202342477A TW 202342477 A TW202342477 A TW 202342477A TW 112107272 A TW112107272 A TW 112107272A TW 112107272 A TW112107272 A TW 112107272A TW 202342477 A TW202342477 A TW 202342477A
Authority
TW
Taiwan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
heteroaryl
compound
Prior art date
Application number
TW112107272A
Other languages
English (en)
Chinese (zh)
Inventor
陸洪福
余華星
丁曉
任峰
Original Assignee
香港商英矽智能科技知識產權有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商英矽智能科技知識產權有限公司 filed Critical 香港商英矽智能科技知識產權有限公司
Publication of TW202342477A publication Critical patent/TW202342477A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112107272A 2022-03-01 2023-03-01 二醯基甘油激酶(DGK) α抑制劑及其用途 TW202342477A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
WOPCT/CN2022/078653 2022-03-01
CN2022078653 2022-03-01
WOPCT/CN2022/091497 2022-05-07
CN2022091497 2022-05-07
WOPCT/CN2022/127020 2022-10-24
CN2022127020 2022-10-24
WOPCT/CN2023/071857 2023-01-12
CN2023071857 2023-01-12

Publications (1)

Publication Number Publication Date
TW202342477A true TW202342477A (zh) 2023-11-01

Family

ID=87883011

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112107272A TW202342477A (zh) 2022-03-01 2023-03-01 二醯基甘油激酶(DGK) α抑制劑及其用途

Country Status (12)

Country Link
US (2) US20240051958A1 (OSRAM)
EP (1) EP4486741A4 (OSRAM)
JP (1) JP2025508971A (OSRAM)
KR (1) KR20240156394A (OSRAM)
CN (1) CN118871438A (OSRAM)
AR (1) AR128669A1 (OSRAM)
AU (1) AU2023227010A1 (OSRAM)
CA (1) CA3244501A1 (OSRAM)
IL (1) IL315015A (OSRAM)
MX (1) MX2024010648A (OSRAM)
TW (1) TW202342477A (OSRAM)
WO (1) WO2023165504A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
AR131785A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinaciones de inhibidores de dgk (diacilglicerol quinasa)
WO2025051110A1 (en) * 2023-09-04 2025-03-13 Insilico Medicine Ip Limited Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
EP1613625A1 (en) 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
WO2011075747A1 (en) 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
WO2017019723A1 (en) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Aza-cyanoquinolinone pde9 inhibitors
CN111406050B (zh) * 2018-01-17 2023-02-03 厦门宝太生物科技股份有限公司 吲哚胺2,3-双加氧酶抑制剂及其用途
RS64641B1 (sr) 2018-06-27 2023-10-31 Bristol Myers Squibb Co Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija
US11866430B2 (en) 2018-06-27 2024-01-09 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
KR20220029719A (ko) 2019-07-04 2022-03-08 리드 파마 홀딩 비.브이. 에스트로겐-관련 수용체 알파 조절제
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
IL291523B2 (en) 2019-10-18 2023-12-01 Lead Pharma Holding Bv Estrogen-related receptor alpha (err-alpha) modulators
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US12478621B2 (en) * 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105116A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
IL294085A (en) 2019-12-19 2022-08-01 Bristol Myers Squibb Co Combinations of dgk inhibitors and checkpoint antagonists
WO2021133751A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
MX2022007130A (es) 2019-12-23 2022-07-11 Bristol Myers Squibb Co Derivados de piperazina sustituidos utiles como activadores de celulas t.
BR112022012220A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
ES3013568T3 (en) * 2019-12-23 2025-04-14 Bristol Myers Squibb Co Substituted heteroaryl compounds useful as t cell activators
EP4445902A3 (en) 2019-12-24 2024-12-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
CA3202330A1 (en) 2020-12-16 2022-06-23 Anthony Casarez Compounds useful as t cell activators
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117836296A (zh) 2021-08-03 2024-04-05 百济神州有限公司 吡唑并吡啶酮化合物
WO2023165525A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023165528A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
EP4486745A4 (en) 2022-03-01 2026-03-11 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023184327A1 (en) 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
JP2025510945A (ja) 2022-03-31 2025-04-15 インベンティスバイオ カンパニー リミテッド キナーゼ阻害剤、その製造方法および用途

Also Published As

Publication number Publication date
JP2025508971A (ja) 2025-04-10
EP4486741A4 (en) 2026-04-08
IL315015A (en) 2024-10-01
CN118871438A (zh) 2024-10-29
EP4486741A1 (en) 2025-01-08
WO2023165504A1 (en) 2023-09-07
US20240051958A1 (en) 2024-02-15
MX2024010648A (es) 2024-11-08
CA3244501A1 (en) 2023-09-07
KR20240156394A (ko) 2024-10-29
AU2023227010A1 (en) 2024-09-12
US12077538B2 (en) 2024-09-03
US20240116935A1 (en) 2024-04-11
AR128669A1 (es) 2024-06-05

Similar Documents

Publication Publication Date Title
AU2020214404B2 (en) Immunomodulators, compositions and methods thereof
TWI912127B (zh) KRas G12D抑制劑
CA2971640C (en) Cot modulators and methods of use thereof
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
TWI627174B (zh) Ｐ２ｘ７調控劑
US12077538B2 (en) Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof
AU2013344049A1 (en) ALK kinase inhibitors
TW202342478A (zh) 二醯基甘油激酶（ＤＧＫ）α抑制劑及其用途
JP2018513150A (ja) チロシンキナーゼ阻害剤およびそれを含む医薬組成物
TWI826535B (zh) 環狀二核苷酸類似物、其藥物組合物及應用
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023165528A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
CN120535527A (zh) 一类含氮稠环类化合物、制备方法和用途
WO2024149389A1 (zh) 取代桥环类抑制剂及其制备方法和应用
US20160297824A1 (en) Imidazo-fused heterocycles and uses thereof
CN121941684A (zh) Cbl-b抑制剂及其使用方法
KR20250073137A (ko) Egfr 억제제 및 그의 용도
AU2023224815A1 (en) Compound as fak inhibitor and use thereof
CN117729921A (zh) 作为pd1/pd-l1抑制剂的化合物及其方法
KR20240093606A (ko) 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도
KR20230158659A (ko) Ctla-4 소분자 분해제 및 그 응용
TW202330519A (zh) 作為ｔａｍ抑制劑的吡唑并吡啶化合物
EA052540B1 (ru) Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения
HK40117800A (zh) 二酰基甘油激酶(DGK)α抑制剂及其用途
CN120712269A (zh) Fgfr2和fgfr3的抑制剂及其用途